Bye bye Amgen OBU! Team Onyx has no pity!
Sandoz’s biosimilar version of Amgen Inc.’s granulocyte colony-stimulating factor Neupogen (filgrastim) is in line potentially to be the first product licensed under this pathway. The application has a March 2015 user fee date, with an FDA advisory committee scheduled for Jan. 7
Sandoz’s biosimilar version of Amgen Inc.’s granulocyte colony-stimulating factor Neupogen (filgrastim) is in line potentially to be the first product licensed under this pathway. The application has a March 2015 user fee date, with an FDA advisory committee scheduled for Jan. 7
Neupogen under fire
Aucun commentaire:
Enregistrer un commentaire